BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 14, 2023 in Boston, MA.

Remedium Bio is excited to announce that the company has been selected as a finalist for the in-person pitch competition at the upcoming Boehringer Ingelheim External Innovation Day.

Matica Biotechnology, Inc. announced the appointment of four experienced leaders in biotechnology and the life sciences to its board of advisors: Charlene Banard, Gerard Fleury, Evan Greger, and Carson Sublett.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023.

The American Society for Reproductive Medicine and Ferring Pharmaceuticals announced a historic $5 million endowment from Ferring to ASRM.

IDEAYA Biosciences, Inc. announces initiation of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.

Abbisko Therapeutics Co., Ltd. announced that the results of the company’s two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference be held in Boston, U.S. These two research results respectively demonstrate the latest preclinical research progress of the next generation of PRMT5*MTA inhibitors and small molecule brain penetrant PD-L1 inhibitors in Abbisko’s pipeline.

Immunic, Inc. announced the presentation of data from the company’s phase 2 CALDOSE-1 trial of vidofludimus calcium in an oral presentation at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.

SwanBio Therapeutics announced the addition of two industry veterans to the company’s leadership team: John Tsai, MD as executive chair, and Christopher “Topher” Brooke as chief operating officer.

Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.